{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:42:23Z","timestamp":1777970543640,"version":"3.51.4"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The aim of this study was to determine the influence of bone turnover markers, namely the N-terminal cross-linking telopeptide (NTx) and alpha C-terminal cross-linking telopeptide of type I collagen (\u03b1-CTx), in detecting bone metastasis (bone-only) in breast cancer (BC) patients, as well as to determine whether this effect is related to changes in bone mineral density (BMD). Materials and Methods: The participants in this study comprised 30 postmenopausal BC patients with bone metastases (age range: 59.56 \u00b1 9.02), 20 postmenopausal BC patients without bone metastases (age range: 55.30 \u00b1 11.55), and 20 healthy postmenopausal female controls (age range: 55.55 \u00b1 5.85). Bone turnover markers (serum NTx and urine \u03b1-CTx) were measured using the ELISA method. A densitometer using dual-energy X-ray absorptiometry (DEXA) was used to analyze the BMD, and tumor markers were measured using the chemiluminescent immunometric assay. Results: The corresponding levels of serum NTx (p = 0.004), parathyroid hormone (PTH) (p = 0.001), and urine \u03b1-CTx (p &lt; 0.001) of BC patients were found to be higher than the standard levels. After the BC patients were divided into subgroups on the basis of the presence of metastasis, the urine \u03b1-CTx levels (p = 0.001) were seen to be at critically high levels in those patients suffering from BC with metastasis. Though the BMD values in the lumbar spine (p &lt; 0.001) and femoral neck (p = 0.001) were found to be significantly low in BC patients, no statistically substantial difference in the BMD levels of BC patients suffering from metastasis was observed. It was observed that urine \u03b1-CTx (specificity: 70%; sensitivity: 85%) values are critical factors that differentiate BC patients with metastasis from BC patients without metastasis. Conclusions: We found that alterations in bone turnover could be detected by using the values of urine \u03b1-CTx while differentiating BC patients with metastasis from BC patients without metastasis. Using the biochemical markers of bone turnover and BMD together would be pertinent for determining the level of metastasis present and examining the efficiency of bone density preservation therapy. Ideally, BMD measurement would be evaluated together with biochemical markers.<\/jats:p>","DOI":"10.3390\/medicina57090880","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:49:51Z","timestamp":1630363791000},"page":"880","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4394-3976","authenticated-orcid":false,"given":"Berrin Papila","family":"Kundaktepe","sequence":"first","affiliation":[{"name":"Department of General Surgery, Faculty of Cerrahpasa Medicine, Istanbul University\u2014Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"Sozer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Yildiz Technical University, 34220 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-4658","authenticated-orcid":false,"given":"Fatih Orkun","family":"Kundaktepe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gaziosmanpa\u015fa Taksim Research and Training Hospital, 34433 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-9098","authenticated-orcid":false,"given":"Sinem","family":"Durmus","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Faculty of Cerrahpasa Medicine, Istanbul University\u2014Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Papila","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Oncology Division, Faculty of Cerrahpasa Medicine, Istanbul University\u2014Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1347-8498","authenticated-orcid":false,"given":"Hafize","family":"Uzun","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Faculty of Cerrahpasa Medicine, Istanbul University\u2014Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonul","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Cerrahpasa Medicine, Istanbul University\u2014Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remise","family":"Gelisgen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Faculty of Cerrahpasa Medicine, Istanbul University\u2014Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-005-9094-7","article-title":"Can bone markers guide more effective treatment of bone metastases from breast cancer?","volume":"97","author":"Clemons","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000500675","article-title":"Expressiveness of bone markers in breast cancer with bone metastases","volume":"97","author":"Zulauf","year":"2019","journal-title":"Oncology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0305-7372(90)90075-Q","article-title":"The pattern of metastases in human breast cancer: Methodological aspects and influence of prognostic factors","volume":"17","author":"Kamby","year":"1990","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.2967\/jnumed.115.157867","article-title":"Imaging bone metastases in breast cancer: Staging and response assessment","volume":"57","author":"Cook","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejogrb.2014.06.021","article-title":"Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography\/computed tomography imaging","volume":"180","author":"Pires","year":"2014","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-013-2431-3","article-title":"Bone mineral density and risk of breast cancer in postmenopausal women","volume":"138","author":"Xinhua","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","first-page":"24","article-title":"Osteoporosis: Using \u2018bone markers\u2019 for diagnosis and monitoring","volume":"51","author":"Arnaud","year":"1996","journal-title":"Geriatrics (Basel Switz.)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast cancer\u2014Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA A Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/annonc\/mdh089","article-title":"Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis","volume":"15","author":"Ali","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_13","first-page":"871","article-title":"Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: Results from the AZURE (BIG01\/04) trial","volume":"110","author":"Brown","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_14","first-page":"1","article-title":"Christiansen, C. Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments","volume":"5","author":"Cloos","year":"2003","journal-title":"Breast Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/CMAR.S155524","article-title":"Bone metastasis pattern in initial metastatic breast cancer: A population-based study","volume":"10","author":"Xiong","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1158\/1055-9965.EPI-05-0909","article-title":"Alpha CTX as a biomarker of skeletal invasion of breast cancer: Immunolocalization and the load dependency of urinary excretion","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","article-title":"Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides","volume":"44","author":"Christgau","year":"1998","journal-title":"Clin. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif. Tissue Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1464-410X.1997.00375.x","article-title":"The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer","volume":"80","author":"Caty","year":"1997","journal-title":"British Journal of Urology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_21","first-page":"305","article-title":"Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients","volume":"7","author":"Morcos","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpba.2004.10.007","article-title":"Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer","volume":"37","author":"Pectasides","year":"2005","journal-title":"J. Pharm. Biomed."},{"key":"ref_23","first-page":"583","article-title":"Markers of bone turnover do not predict bone metastases in breast cancer","volume":"48","author":"Seibel","year":"2002","journal-title":"Clin. Lab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0093-7754(01)90233-7","article-title":"Use of markers of bone turnover for monitoring bone metastases and the response to therapy","volume":"28","author":"Lipton","year":"2001","journal-title":"Semin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/880\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:06Z","timestamp":1760165586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/9\/880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["medicina57090880"],"URL":"https:\/\/doi.org\/10.3390\/medicina57090880","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}